Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€95.81

€95.81

-0.840%
-0.81
-0.840%
€116.71
 
24.05.24 / Tradegate WKN: 850103 / Symbol: ABT / Name: Abbott / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Abbott Laboratories Stock

The price for the Abbott Laboratories stock decreased slightly today. Compared to yesterday there is a change of -€0.810 (-0.840%).
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Abbott Laboratories.
As a result the target price of 116 € shows a positive potential of 21.07% compared to the current price of 95.81 € for Abbott Laboratories.
Criterium "Brand" is seen as the biggest plus for Abbott Laboratories stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Abbott Laboratories in the next few years

Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Abbott Laboratories vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Abbott Laboratories -0.840% 0.063% -4.084% -1.002% -3.960% -0.405% 39.909%
Pfizer Inc. 0.110% 1.025% 8.454% -25.953% 1.992% -18.543% -25.230%
Elanco Animal Health Inc. 0.590% -2.112% 24.513% 98.233% 14.512% -47.250% -
Biogen Inc. -0.790% -5.233% 6.518% -28.368% -14.758% -12.150% -0.495%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-01

Examining the financials of the pharmaceutical giant Abbott Laboratories, with its ticker symbol ABT, one can't help but form an initial impression tinged with intrigue. Abbott stands as a prominent entity in the healthcare sector, known for its diversified portfolio ranging from medical devices to nutritional products and branded generic medications. This diversity is reflected in its robust financial statements, showcasing the company's significant market presence and operational efficiency.

The sheer magnitude of Abbott's total assets, which hovered consistently above the $70 billion mark from 2020 to 2022, signals a company with considerable resources and a solid financial foundation. Across the same period, the evolution of its balance sheet reveals a healthy balance between liabilities and stockholder equity, pointing to sound financial management. The company's liquidity, as illustrated by its cash reserves, provides confidence in Abbott's ability to meet short-term obligations and invest in growth opportunities.

Profitability and Revenue Streams Abbott has demonstrated an admirable profit margin and a stable operating margin, hinting at its efficiency in converting revenue into profit and managing its operational expenses. The company's net income has shown relative growth, especially when evaluating the year-over-year rise from 2020 to 2022, indicating a consistent upward trajectory in profitability.

Comments

Prediction Buy
Perf. (%) -0.99%
Target price 109.789
Change
Ends at 22.05.25

Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Citigroup Inc. from $128.00 to $119.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -4.97%
Target price 131.544
Change
Ends at 22.04.25

Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Barclays PLC from $141.00 to $140.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -2.90%
Target price 117.413
Change
Ends at 19.04.25

Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Royal Bank of Canada from $128.00 to $125.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Show more

News

Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q1 2024 Earnings CallApr 17, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Abbott Laboratories Outlook is Healthy: Buy the Dip: https://www.marketbeat.com/logos/articles/med_20240417090953_chart-abt-4172024ver001.png
Abbott Laboratories Outlook is Healthy: Buy the Dip

Abbott Laboratories' (NYSE: ABT) share price was corrected at the end of CQ1 2024 on growth, profitability and capital returns concerns. The FQ1 results, however, belie the fear and have the market

Want Decades of Passive Income? 2 Stocks to Buy Now.: https://g.foolcdn.com/editorial/images/769462/physician-shaking-patients-hand.jpg
Want Decades of Passive Income? 2 Stocks to Buy Now.

Dividend-paying stocks have generally outperformed those that don't pay dividends over the long term. That's partly because maintaining a healthy dividend requires a solid underlying business. And